Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM).
1. Eli Lilly
Eli Lilly has been one of the best-performing pharmaceutical giants in the past 10 years. Though that doesn't guarantee future success, it's worth highlighting what has led to the company's strong showing. Lilly has made significant clinical breakthroughs in recent years, none more important than tirzepatide, a medicine sold as Mounjaro in treating diabetes, and Zepbound in managing weight. It was the first dual GLP-1/GIP agonist approved by the U.S. Food and Drug Administration.
Here are two ways in which that's relevant to the company's future performance.
First, tirzepatide hasn't been on the market that long, having earned approval about three years ago. It will continue delivering excellent top-line growth.
Second, even more clinical successes like tirzepatide could help the stock perform well. Eli Lilly recently released positive data from a phase 3 clinical trial for orforglipron, an oral GLP-1 medicine; the strong results sent the stock price soaring.
The drugmaker is also working on retatrutide, which mimics the action of not just two gut hormones (as tirzepatide does), but three. Lilly dubbed it "triple G." Retatrutide could be yet another breakthrough. In total, the company has 11 weight loss candidates in the pipeline. Even with mounting competition in this field, Eli Lilly looks like a runaway leader compared to any company not named Novo Nordisk.
And that's before we mention the rest of the pipeline. Last year, Lilly earned approval for Kisunla in treating Alzheimer's disease, another significant win considering that very few medicines have gotten the green light from regulators in this area in the past 20 years.
Lilly has not performed well in 2025 due to tariff-induced volatility, and disappointing bottom-line guidance for the full year. However, the company is pivoting its manufacturing back into the U.S., something it has been doing for years -- so even if President Donald Trump's trade agenda survives his administration, the drugmaker should be fine.
And while the stock's forward price-to-earnings ratio of around 33 is around twice the average of 16 for the healthcare industry, the company's better-than-average results and excellent prospects justify its valuation.
Eli Lilly is a terrific dividend stock. The company has increased its payouts by 200% over the past 10 years. And the stock should deliver superior returns through 2035, especially for shareholders who opt to reinvest the dividend.
2. DexCom
DexCom specializes in developing and marketing continuous glucose monitoring (CGM) systems that help diabetes patients keep track of their blood sugar levels. The company's appeal is the superiority of its devices compared to the alternatives. With blood glucose meters, patients use a painful finger prick (or something similar) to collect a small blood sample to know their measurement at that specific point in time. In contrast, once installed, CGMs constantly monitor their status, day and night, with measurements made up to every five minutes. That's 12 per hour and 288 per day -- no manual meter can match that.
Strong adoption of the technology has been a massive tailwind for DexCom. Patients are switching to CGM, and third-party payers are increasingly reimbursing for it. This has resulted in growing revenue and earnings over the past decade, and a strong, if somewhat volatile, stock-market performance.
DXCM Revenue (Annual) data by YCharts.
Here's more good news: DexCom has consistently pointed out that the CGM market remains underpenetrated. In the U.S., the number of diabetes patients who use CGM is much lower than the number whose use would be covered by insurance. Furthermore, the company has routinely entered new markets to expand its addressable population.
DexCom does have to deal with stiff competition from Abbott Laboratories, but has remained successful nonetheless. Abbott pointed out about 18 months ago that just 1% of diabetic adults worldwide had access to CGM. So there's space for multiple winners over the long run.
And while tariffs could be a threat, DexCom does significant manufacturing for U.S. consumers domestically. Management expects minimal impact from tariffs.
Lastly, though DexCom's recent forward P/E of around 42 looks high, it's not far from the lowest point it has seen in years:
DXCM PE Ratio (Forward) data by YCharts.
A high-growth stock, DexCom has generally traded at high premiums and has still performed better than the broader market. Its valuation won't kill momentum in the next decade. And in the meantime, the stock should once again deliver outsize returns as DexCom makes headway into the massive CGM market.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!*
Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
38 minutes ago
- CTV News
Lufa Farms partners with Walmart to grow and sell greenhouse produce
With Walmart Canada, Montreal's Lufa Farms will grow produce under a 127,000 square foot greenhouse roof. Lufa Farms partners with Walmart to grow and sell greenhouse produce A partnership involving Lufa Farms is giving buying local a whole new meaning. 'We want to use free space in the cities where the people are and live,' says Lionel Trombert, Lufa Farms vice-president of finance. With Walmart Canada, the food company is taking produce from local to hyperlocal under one 127,000 square foot greenhouse roof. 'Whatever is being grown here is being picked and harvested at night and given to our customers either through the Lufa websites and, in this case, through the Walmart kiosk downstairs on a fresh basis every morning,' Trombert says. From cucumbers to peppers, it's the first time Lufa Farms produce is being sold through a retailer. This is also the first time that Walmart Canada is selling produce from its own roof. On top of filling a demand to buy locally, the partnership is a solution that offers sustainability. Lufa Farms greenhouse Lufa Farms is teaming up with Walmart to grow produce under a 127,000 square foot greenhouse roof. (Anastasia Dextrene/CTV) 'Land and water have become scarce resources and hydroponic systems usually typically consumes only about 5 to 10 per cent of the water of a land farm,' says Trombert. Their site at Marché Central is pesticide-free and you won't find soil or dirt. Instead, you'll find a hydraulic system that's responsible for producing four tonnes of crops each day. The location was chosen as the perfect basis for the project's roots, due to its size and proximity to neighbourhoods. Walmart Canada market leader Jacinthe Langevin says the company purchased more than $3.8 billion worth of products from 460 Quebec retailers last year. 'We are so proud to add Lufa Farms officially to that list,' she said. The hope is that the project will keep growing. 'There's an ask from customers and we've experienced that when we first sold those products ... we sold out almost every day,' Langevin told CTV.
CTV News
39 minutes ago
- CTV News
Air quality statement issued for Calgary: ECCC
An air quality statement was issued for Calgary Sunday morning. An air quality statement was issued for Calgary Sunday morning as wildfire smoke rolled into the region. Environment and Climate Change Canada (ECCC) posted on its website at 8:06 a.m. that 'wildfire smoke is causing poor air quality and reduced visibility in some areas." It said that conditions were expected to improve later in the day Sunday. The air quality index Sunday at 9:23 a.m. was 7, or 'high-risk.' For more information about wildfire smoke and its impact on your health, go here.
CTV News
40 minutes ago
- CTV News
Mike Johnson downplays Musk's influence and says Republicans will pass Trump's tax and budget bill
Speaker of the House Mike Johnson, R-La., wraps up a news conference on U.S. President Donald Trump's bill of tax breaks and spending cuts, at the Capitol in Washington, Wednesday, June 4, 2025. (AP Photo/J. Scott Applewhite) With an uncharacteristically feistiness, Speaker Mike Johnson took clear sides Sunday in U.S. President Donald Trump's breakup with mega-billionaire Elon Musk. The Republican House leader and staunch Trump ally said Musk's criticism of the GOP's massive tax and budget policy bill will not derail the measure, and he downplayed Musk's influence over the GOP-controlled Congress. 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' 'What we're trying to do is help hardworking Americans who are trying to provide for their families and make ends meet,' Johnson insisted. Johnson said he has exchanged text messages with Musk since the former chief of Trump's Department of Government Efficiency came out against the GOP bill. Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk. The speaker was dismissive of Musk's threats to finance opponents — even Democrats — of Republican members who back Trump's bill. 'We've got almost no calls to the offices, any Republican member of Congress,' Johnson said. 'And I think that indicates that people are taking a wait and see attitude. Some who may be convinced by some of his arguments, but the rest understand: this is a very exciting piece of legislation.' Johnson argued that Musk still believes 'that our policies are better for human flourishing. They're better for the US economy. They're better for everything that he's involved in with his innovation and job creation and entrepreneurship.' The speaker and other Republicans, including Trump's White House budget chief, continued their push back Sunday against forecasts that their tax and budget plans will add to annual deficits and thus balloon a national debt already climbing toward $40 trillion. Johnson insisted that Musk has bad information, and the speaker disputed the forecasts of the nonpartisan Congressional Budget Office that scores budget legislation. The bill would extend the 2017 Trump tax cuts, cut spending and reduce some other levies but also leave some 10.9 million more people without health insurance and spike deficits by $2.4 trillion over the decade, according to the CBO's analysis. The speaker countered with arguments Republicans have made for decades: That lower taxes and spending cuts would spur economic growth that ensure deficits fall. Russell Vought, who leads the White House Office of Budget and Management, said on Fox News Sunday that CBO analysts base their models of 'artificial baselines.' Because the 2017 tax law set the lower rates to expire, CBO's cost estimates, Vought argued, presuming a return to the higher rates before that law went into effect. Vought acknowledged CBO's charge from Congress is to analyze legislation and current law as it is written. But he said the office could issue additional analyses, implying it would be friendlier to GOP goals. Asked whether the White House would ask for alternative estimates, Vought again put the burden on CBO, repeating that congressional rules allow the office to publish more analysis. Other Republicans, meanwhile, approached the Trump-Musk battle cautiously. 'As a former professional fighter, I learned a long time ago, don't get between two fighters,' said Oklahoma Sen. Markwayne Mullin on CNN's 'State of the Union.' He even compared the two billionaire businessmen to a married couple. 'President Trump is a friend of mine but I don't need to get, I can have friends that have disagreements,' Mullin said. 'My wife and I dearly love each other and every now and then, well actually quite often, sometimes she disagrees with me, but that doesn't mean that we can't stay focused on what's best for our family. Right now, there may be a disagreement but we're laser focused on what is best for the American people.' Bill Barrow, The Associated Press Associated Press journalist Gary Fields contributed from Washington.
